Vendor Intelligence Report: Lisa Biopeptide

Executive summary

Across 54 Finnrick lab tests, Lisa Biopeptide posts a 74% overall pass rate: 40 pass and 14 fail. That headline does not tell the buyer enough. The tested catalog is uneven, not uniformly broken: GHK-Cu is the strongest lane, while BPC-157 is the clearest avoid. Retatrutide sits in the middle but is dragged by variability and batch-traceability weakness, and Tirzepatide carries the highest-severity product finding: a vial sold as Tirzepatide that did not contain Tirzepatide.

The practical read is directional. Lisa may be a less adverse choice for a buyer already fixed on this vendor and buying GHK-Cu; it is not a vendor we would steer a risk-conscious Tirzepatide or BPC-157 buyer toward on current evidence. Ratings also compress under tighter methodologies, which matters where underfill and purity outliers sit behind otherwise acceptable-looking aggregate numbers.

Beyond the lab data, the identity work raises transparency concerns. The website uses corporate manufacturer language, but registry searches did not verify Lisa Biopeptide Limited or Lisa Biopeptides Co., Ltd., and no address or officers are disclosed. The domain was registered in September 2025, while site articles display earlier 2024 dates; a Chinese 35.com platform account, Baidu SEO script, Hong Kong server, Gmail contact, multiple Hong Kong WhatsApp numbers, and a Telegram handle create a coherent China-linked direct-sales footprint rather than a verified manufacturer profile.

The report also tracks buyer-recourse and brand-confusion issues: personal or informal payment rails reported in community sources, mixed low-volume reviews, and Lisa-branded impersonation attempts in direct messages. None of this proves every order fails; some buyers report delivery. It does mean product choice, batch-tied COAs, and channel authentication matter more here than the vendor’s broad catalog claims.

Inside the full report:

• Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 5 tested products
• Tirzepatide certificate trail covering the wrong-identity failure and a separate severe underfill/purity outlier
• Retatrutide quality-over-time analysis, including missing batch-ID patterns and COA-transferability risk
• Corporate registry checks, domain/RDAP timeline, certificate-transparency dates, and backdated article evidence
• 35.com infrastructure notes, platform account identifier, Telegram/WhatsApp contact map, and payment-recourse assessment
• Trustpilot, ScamAdviser, rapamycin.news, Reddit/NorgePeptider reputation and impersonation evidence

Risk assessment

• Tirzepatide identity and potency risk — high: One Tirzepatide vial contained no Tirzepatide; another tested at 74.5% purity with a −60% quantity shortfall.
• BPC-157 quality risk — high: BPC-157 has a 43.06% Finnrick rating with 1 pass and 3 fail across 4 tests.
• Retatrutide consistency and batch-traceability risk — medium: Retatrutide is 74.11% with 19 pass and 7 fail across 26 tests; field-reviewed records also showed missing batch IDs and a decline toward April 2026.
• Corporate transparency and legal-entity concern — high: No matching registry record, no disclosed address or officers, WHOIS privacy, and inconsistent jurisdiction signals.
• Marketing-history and facility-claim deception concern — high: Backdated 2024 article dates, unverified factory imagery, unsupported 15+ years and 50,000+ factory-area claims, and ISO90001 wording.
• Payment and transaction-recourse risk — high: Reported personal Revolut, crypto, Western Union and informal WhatsApp/Gmail channels provide weak recourse if shipment or testing fails.
• Copycat / brand-confusion risk — medium: Reddit documented Lisa-brand impersonation, while the vendor lacks a public authorized-channel list, anti-counterfeit flow, or signed COA verification system.